Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17508611 | 0.85 | KDM4E (0.41) | GRM2TP53SMN1; SMN2TSHRLMNA | |
| SCHEMBL1045552 | 0.79 | POLB (0.43) | GRM2SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL3326163 | 0.76 | GRM2 (0.47) | GRM2SMN1; SMN2TSHRLMNAHPGD | |
| SCHEMBL3659742 | 0.75 | ACHE (0.46) | SMN1; SMN2TSHRLMNAHPGDMEN1 | |
| SCHEMBL29136175 | 0.74 | SLC9A1 (0.58) | SMN1; SMN2TSHRLMNAHPGDMEN1 | |
| SCHEMBL3321570 | 0.74 | GRM2 (0.49) | GRM2L3MBTL1SMN1; SMN2TSHRLMNA | |
| SCHEMBL570746 | 0.72 | SLC9A1 (0.44) | GRM2L3MBTL1TP53SMN1; SMN2TSHR | |
| SCHEMBL29199475 | 0.69 | SLC9A1 (0.47) | GRM2L3MBTL1TP53TSHRLMNA | |
| SCHEMBL570412 | 0.69 | TDO2 (0.39) | TSHRHPGDMEN1KMT2AGAA | |
| SCHEMBL2328936 | 0.69 | RECQL (0.60) | GRM2L3MBTL1TP53SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816529-B2 | Pyrimidines useful as modulators of voltage-gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-19 | — | — | US | claimed |
| WO-1999035132-A1 | HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1999-07-15 | — | — | WO | claimed |
| CN-108738320-B | cGMP modulators for the treatment of cardiovascular diseases | 默沙东公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3609883-A1 | FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018188590-A1 | FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-10-18 | — | — | WO | disclosed |
| US-8324220-B2 | Pyrimidines useful as modulators of voltage-gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110003814-A1 | PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-06 | — | — | US | disclosed |
| US-7816529-B2 | Pyrimidines useful as modulators of voltage-gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1638955-A2 | PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050049247-A1 | Pyrimidines useful as modulators of voltage-gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2005-03-03 | — | — | US | disclosed |
| WO-2005003099-A2 | PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-1999035132-A1 | HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003814-A1 | PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS | KCNJ1, KCNJ11, TRPV1 | GRM2 216/4885L3MBTL1 3949/4885TP53 3993/4885 |
| US-20050049247-A1 | Pyrimidines useful as modulators of voltage-gated ion channels | KCNJ1, KCNJ11, TRPV1 | GRM2 216/4885L3MBTL1 3949/4885TP53 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.